Velactis
cabergoline
Table of contents
Overview
The marketing authorisation for this product has not been renewed by the marketing authorisation holder and is now withdrawn.
Authorisation details
| Product details | |
|---|---|
| Name |
Velactis
|
| Agency product number |
EMEA/V/C/003739
|
| Active substance |
cabergoline
|
| International non-proprietary name (INN) or common name |
cabergoline
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QG02CB03
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Ceva Santé Animale
|
| Revision |
1
|
| Date of issue of marketing authorisation valid throughout the European Union |
09/12/2015
|
| Contact address |
10 Avenue de la Ballastiere
33500 Libourne France |
Product information
11/12/2020 Velactis - EMEA/V/C/003739 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Genito urinary system and sex hormones
-
Other gynecologicals
-
Prolactine inhibitors
Therapeutic indication
For use in the herd management programme of dairy cows as an aid in the abrupt drying-off by reducing milk production to:
- reduce milk leakage at drying off;
- reduce the risk of new intramammary infections during the dry period;
- reduce discomfort.